Trends in obesity among U.S. active component service members (ACSMs) and civilians are relevant to military recruitment and retention, as excess body weight is a common disqualification for military service. This study utilized measured height and weight data from the Military Health System Data Repository for ACSMs (cumulative n=12,262,745) and the National Health and Nutrition Examination Survey for civilians ages 17-62 years (cumulative n=19,334). Accounting for the design of each data source, the prevalence of obesity (body mass index≥30 kg/m2) and body mass index (BMI) distributions were calculated. Joinpoint software and polynomial regression regression were used to assess trends over time. From 2013 through 2023, obesity prevalence increased among ACSMs, from 14.7% to 24.2%. Although obesity rates among civilians were consistently higher, this gap narrowed over the course of the decade. The same pattern was seen in young men (ages 17-24 years). Civilians have greater proportions within the highest classes of BMI than ACSMs. Persistently high obesity prevalence among ACSMs overall and in young men, particularly since 2019, may affect military recruitment, retention, and ultimately, strength and readiness. From 2013 through 2023, the prevalence of obesity increased significantly among U.S. ACSMs, 2019 to 2023 in particular, while prevalence among civilians remained consistently high. The pattern of obesity is especially relevant in young men, the largest source of potential and newly accessed military recruits.
The 2023 American Academy of Pediatrics clinical practice guideline (CPG) recommends testing children aged ≥ 10 years with obesity for abnormalities in lipids, glucose metabolism, and liver function. We aimed to assess laboratory screening and test results for three obesity-related chronic conditions in a large cohort of US patients 10-18 years with obesity. We used electronic health record data to estimate (1) prevalence of screening for diabetes, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), individually and in combination, and (2) prevalence of abnormal test results, by obesity severity and demographics. Among 333,110 patients with obesity, only one-quarter (26%) were screened for diabetes, dyslipidemia, or NAFLD during 2020-2022. Among those screened, complete screening (all three conditions) occurred half of the time. Screening rates were significantly higher in those with more severe obesity, yet 64% of children with class 3 obesity remained unscreened. When screening occurred, results revealed a high proportion of abnormal lipid (56%), NAFLD (44% elevated or borderline), and diabetes markers (14% prediabetes or diabetes). Most youth with obesity were not screened for chronic conditions. Many who were screened had abnormal results. These findings establish baseline estimates and highlight opportunities for improvement in uptake of CPG recommendations to support evidence-based obesity pediatric care.
Pediatric obesity is a global public health concern. Obesity-related physiological changes may affect the pharmacokinetics of drugs and lead to therapeutic failure or toxicities. An earlier review of pediatric drug development programs from 2007 to 2016 found that, of 89 programs listing obesity-related terms, only 4 (4%) products described pharmacokinetic changes associated with obesity. This review examined obesity considerations for 185 drug products for which pediatric drug development programs were submitted to the US Food and Drug Administration (FDA) between 2016 and 2021. The FDA-authored review documents and drug product labeling were queried for obesity-related terms and the review found 97/185 (52%) drug products had obesity-related terms in these sources. Of the 97 drug products, 55/97 (57%) had obesity-related terms in the FDA-authored reviews only, 13/97 (13%) had obesity-related terms in the drug product labeling only, and 29/97 (30%) had obesity-related terms in both FDA-authored reviews and drug product labeling. Most of the obesity-related information in the drug product labeling originated from data collected from adults. Only 13/185 (7%) drug product labeling contained obesity-related terms in reference to drug pharmacokinetics. Specific dosage recommendations for the use of the drug products in pediatric patients who are obese remain lacking. The dearth of available information to guide drug dosages in the obese pediatric population suggests that further research, innovative approaches, and evidence-based guidelines are needed to inform the optimal therapeutic use of drugs in this population.
This study aimed to identify key childhood obesity correlates in Southern California by analyzing individual components from four social determinants of health (SDoH) indices and explore their interactions. We utilized publicly available data from 330 cities across 10 counties, incorporating childhood obesity rates from the 2019 California Department of Education Physical Fitness Test (684,419 children, 40% Latino). Fifty-two individual SDoH were obtained from the Healthy Places Index, Social Vulnerability Index, CalEnviroScreen, and Child Opportunity Index (2015-2019). Weighted quantile sum regression and an interpretable machine-learning tool were used to identify which individual SDoH were significantly associated with childhood obesity. We identified a SDoH mixture associated with increased percentile of childhood obesity (β [95% CI]: 10.1 [8.1, 12.1]). Fourteen factors significantly contributed, with the top six being school poverty, minority status, asthma emergency room visits, public assistance rates, hazardous waste sites, and lead exposure from housing. We also found positive associations between Latino percentage and key correlates. Cities with high school poverty and low-income housing burdens had higher obesity rates. This analysis moved beyond composite indices to examine specific SDoH observed alongside childhood obesity in Southern California, drawing attention to dimensions related to school, healthcare, social services, and environmental exposures.
Obesity, or excessive body fat, is a significant health risk factor. Western diets (WD) contribute to metabolic dysfunction and obesity, while Mediterranean diets (MD) improve metabolic health. This study examined the contrasting effects of WD versus MD on visceral and subcutaneous adipose tissues (VAT, SAT) using a randomized preclinical trial in 38 female cynomolgus macaques assigned to consume either WD (n = 21) or MD (n = 17) for 31 months. Body composition, metabolic parameters, and adipose transcriptomics were evaluated. WD significantly induced VAT and SAT accumulation, which was directly associated with insulin resistance, hepatosteatosis, and time spent alone and inversely related to cortisol suppression response to dexamethasone indicating hypothalamic-pituitary glucocorticoid insensitivity. Diet significantly influenced the VAT transcriptome, with MD upregulating pathways linked to RNA processing and protein folding while downregulating those involved in fatty acid oxidation and aerobic respiration. These findings highlight the protective role of MD against fat accumulation and metabolic dysfunction and provide novel insights into the molecular mechanisms underlying diet-induced obesity. Promoting this dietary pattern may help reduce obesity and chronic disease risk. Further research integrating proteomics and metabolomics is required to better understand diet-induced molecular changes.
People with early-onset obesity (diagnosed at age < 25 years) may present with more cardiometabolic abnormalities and obesity-related complications. This post hoc analysis assessed baseline characteristics and body weight (BW) changes with tirzepatide in people with early- versus later-onset obesity. Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included. Baseline characteristics and changes in BW and cardiometabolic risk factors at 72/88 weeks were assessed. In SURMOUNT-1, participants with early- versus later-onset obesity had longer mean obesity duration (20 ± 12 vs. 11 ± 8 years), higher BMI (40 ± 7 vs. 37 ± 6 kg/m2) and waist circumference (WC, 118 ± 16 vs. 112 ± 14 cm), and lower HbA1c (5.48% ± 0.4% vs. 5.60% ± 0.4%), triglycerides (median 120 vs. 130 mg/dL), and systolic blood pressure (SBP; 121 ± 13 vs. 125 ± 13 mmHg) at baseline (all p ≤ 0.004). At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups. Similar improvements were observed in SURMOUNT-3 and SURMOUNT-4. In this post hoc analysis, participants with early- versus later-onset obesity exhibited a mixed profile of metabolic health at baseline, including a higher degree of central adiposity and lower HbA1c and SBP. Improvements in BW and cardiometabolic markers with tirzepatide were similar between subgroups. ClinicalTrials.gov identifiers: NCT04184622, NCT04657016, NCT04660643.
This meta-analysis evaluates the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for the treatment of older adults with obesity compared to younger individuals. A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381). PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP-1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes. Random effects meta-analyses calculated the log odds ratios (LOR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, with equivalence testing via two one-sided tests (TOST) and meta-regression for baseline adjustments. Five studies involving 1229 participants were included. No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, p = 0.9). Older adults had a trend toward lower frequency of nausea (LOR: -0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001). Efficacy in metabolic and weight control was comparable. Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia. GLP-1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
The Food Craving Inventory (FCI) measures the frequency of food cravings along five dimensions: overall food cravings, cravings for sweets, cravings for high-fat food, cravings for starchy food, and cravings for fast food. Evidence of the influence of current hunger on FCI scores is equivocal and challenged by methodological limitations, including the use of self-reported hunger and the lack of control for phase of the menstrual cycle. We aimed to examine (1) the potential association of objective, behaviorally measured hunger (hours since last caloric intake; FAST) with responses on the FCI, controlling for the influence of the menstrual cycle and (2) the relationships of the FCI with weight-related measures (i.e., body mass index, BMI; body weight, BW; body fat percentage, BF) in individuals with obesity. Thirty-two adults with obesity (BMI 30-39.9 kg/m2) were included. Subjects' BW and BF were measured via bioelectrical impedance, and BMI was calculated. On a separate day, subjects were administered the FCI after an intended 8-h fast. For premenopausal women, this was during the second half of the follicular phase of their menstrual cycle. Linear correlations between FCI subscales and each of BW, BMI, BF and FAST were performed. FAST correlated with cravings for sweets (r = 0.381, p = 0.034) and showed a trend for overall cravings (r = 0.331, p = 0.069). BW, BMI, and BF did not correlate with any of the FCI subscales. Our results show that current, objective, behaviorally defined hunger (FAST) may influence FCI scores after controlling for menstrual cycle phase. However, FCI scores showed no relationship to BMI, BW, or BF, indicating that FCI scores may not reflect enduring patterns related to long-term weight gain. Future research should use objective hunger measures as covariates when interpreting FCI data and should exercise caution in treating FCI scores as indicators of long-term obesity risk.
The objective of this study was to examine whether obesity without preexisting or gestational comorbidities is associated with postpartum hospital use (PHU). We studied 2016 to 2018 birth certificate and discharge data on 178,729 New York City births without International Classification of Diseases, Tenth Revision (ICD-10) codes at delivery for diabetes; hypertension; placental disease; anemia; thyrotoxicosis; bariatric surgery; and pulmonary, cardiac, renal, bleeding, autoimmune, digestive, neuromuscular, mental, or substance-use disorders. We defined PHU as ≥1 readmission or emergency department visit within 30 days of delivery discharge. We used ICD-10 codes to specify postpartum hypertension, infection, or hemorrhage during PHU (i.e., "cause-specific PHU") because these are leading mortality causes. We examined associations between prepregnancy BMI and PHU using multivariable logistic regression. PHU incidence was 3.7% for those with normal weight, 5.1% for those with overweight, 6.3% for those with class 1 or 2 obesity, and 9.1% for those with class 3 obesity. A positive association persisted after adjustment. Obesity was associated with cause-specific PHU of postpartum hypertension (adjusted odds ratio [aOR]: 2.2, 95% confidence limits [CL]: 1.8-2.7, normal weight referent) and wound infection (aOR: 1.5, 95% CL: 1.2-1.8), but not hemorrhage (aOR: 0.9, 95% CL: 0.7-1.3), mastitis, or genitourinary infection (aOR: 1.1, 95% CL: 0.9-1.3). Among individuals without other comorbidities, elevated BMI was associated with PHU. Findings can inform obstetric management to reduce morbidity during the critical fourth trimester.
This study examined racial differences in weight loss and clinical response to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy among adults with obesity using real-world data. We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records (EHRs) from adults aged 18 years and older. EHR data from the University of Mississippi Medical Center RDW were analyzed for 7214 adults (2182 White; 5032 Black) prescribed injectable GLP-1RA between 2015 and 2025. Inclusion criteria were BMI ≥ 30 kg/m2 and ≥ 1 GLP-1RA. Longitudinal changes in patient data were modeled using generalized additive mixed models. At 2.5 years, White individuals experienced significantly greater body weight loss than Black individuals: -7.1% (95% CI -8.0%, -6.2%) versus -4.9% (95% CI -5.4%, -4.3%), as well as significantly larger reductions in estimated glomerular filtration rate, systolic blood pressure, and HbA1c. Semaglutide and tirzepatide were associated with the greatest improvements. Renal function decline was attenuated in both groups after therapy. In a large, diverse EHR cohort, GLP-1RA therapy was associated with significant weight, glycemic, and renal benefits that were attenuated in Black adults. These findings highlight the urgent need to understand mechanisms contributing to variable GLP-1RA outcomes among different populations.
Pediatric obesity is associated with insulin resistance, which, in turn, impacts glucose and lipid metabolism. This study sought to assess how glucose variability relates to intrahepatic fat content, β cell insulin sensitivity, and glycolysis in youth with obesity. A total of 27 youth with obesity (11 girls, BMI percentile, median [25th-75th percentiles]: 99.0 [97.9-99.0]) wore a continuous glucose monitoring device for 10 days and underwent a 3-h oral glucose tolerance test. β cell function was assessed using the oral minimal model, and liver proton density fat fraction was measured by magnetic resonance imaging. Average sensor-derived glucose and glucose standard deviation (STDEV) and coefficient of variation (CV) were associated with liver proton density fat fraction (p = 0.0130, p = 0.0005, and p = 0.0028, respectively). First-phase insulin secretion, basal insulin secretion, and insulin sensitivity were associated with STDEV (p = 0.0344, p = 0.0091, and p = 0.0031, respectively) and CV (p = 0.0128, p = 0.0012, and p = 0.0022, respectively). STDEV and CV were also associated with 2-h glucose (p = 0.0067 and p = 0.0324, respectively) and plasma lactate (p = 0.0030 and p = 0.0123, respectively). Daily glucose variability is associated with the degree of intrahepatic fat content, postprandial glucose, and plasma lactate concentrations.
Hypertension and obesity are major public health problems in the United States and Maryland. To assess the impact of Medication Therapy Management (MTM) on controlling hypertension and obesity in a sample in Southern Maryland: Prince George's, Calvert, Charles, and St. Mary's counties. 171 patients with high blood pressure were enrolled in an MTM program for 12 months. Patients received at least one pharmacist consultation between September 2021 and September 2023. We employed a pre-post prospective study design to assess the impact of MTM on patients' blood pressure management. We examined the association between MTM and systolic blood pressure (SBP) and diastolic BP (DBP) as the primary outcome, and weight and body mass index (BMI) as secondary outcomes. We used descriptive analysis and fixed effect regression models to present the association between outcome variables and enrollment time in the program. Our findings showed that the MTM reduced uncontrolled hypertension by 17.5 percentage points, weight by 3.6lbs (10.2), and BMI by 0.6 kg/m2 (2.1). The regression model showed that the MTM intervention reduced the prevalence of uncontrolled hypertension (-1.81, CI: [-3.11, -0.51]), and obesity (BMI > 30, -1.85 (CI: [-3.12, -0.57]), by 12 months of enrolling in the program. During this time SBP reduced to -10.37 mmHg (CI: [-19.62, 1.2]). Our results suggest that policymakers should prioritize promoting MTM services as an effective means of blood pressure control. Combining a community health worker (CHW) model with community-based pharmacists can further improve health outcomes for patients with hypertension.
Obesity, which is defined as having a body mass index of 30 kg/m2 or greater, has been recognized as a serious health problem that increases the risk of many comorbidities (eg, heart disease, stroke, and diabetes) and mortality. The high prevalence of individuals who are classified as obese calls for additional considerations in clinical trial design. Nevertheless, gaining a comprehensive understanding of how obesity affects the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of drugs proves challenging, primarily as obese patients are seldom selected for enrollment at the early stages of drug development. Over the past decade, model-informed drug development (MIDD) approaches have been increasingly used in drug development programs for obesity and its related diseases as they use and integrate all available sources and knowledge to inform and facilitate clinical drug development. This review summarizes the impact of obesity on PK, PD, and the efficacy of drugs and, more importantly, provides an overview of the use of MIDD approaches in drug development and regulatory decision making for patients with obesity: estimating PK, PD, and efficacy in specific dosing scenarios, optimizing dose regimen, and providing evidence for seeking new indication(s). Recent review cases using MIDD approaches to support dose selection and provide confirmatory evidence for effectiveness for patients with obesity, including pediatric patients, are discussed. These examples demonstrate the promise of MIDD as a valuable tool in supporting clinical trial design during drug development and facilitating regulatory decision-making processes for the benefit of patients with obesity.
The objective of this study was to examine the representation of historically marginalized racial and ethnic groups in pediatric obesity clinical trials. We performed a cross-sectional analysis of clinical trials in pediatric obesity (participants aged ≤18 years) that were registered in ClinicalTrials.gov, were completed from January 2013 to August 2023, and were conducted in the United States. We quantified disparities in trial enrollment by calculating the enrollment-prevalence disparity (EPD) for each racial and ethnic group. A total of 260 trials met eligibility criteria, of which 128 trials (49.2%) reported race and/or ethnicity data. Enrollment of White, Hispanic, and Black children roughly reflects disease burden in these populations. However, relative to disease burden, Asian (EPD, -3.7%; IQR, -3.7% to 1.8%; p < 0.0001), American Indian and Alaska Native (EPD, -2.1%; IQR, -2.1% to -2.1%; p < 0.0001), and Native Hawaiian or other Pacific Islander (EPD, -0.6%; IQR, -0.6% to -0.6%; p < 0.0001) children were significantly underrepresented in these trials. With the exception of Black and Hispanic children, historically marginalized racial groups were underrepresented in pediatric obesity trials, signifying a need to improve diversity of participants in these trials. Additionally, there are substantial gaps in the documentation of race and ethnicity information. Concerted efforts are needed to ensure adequate reporting of race and ethnicity information in clinical trials.
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management of patients with obesity. The perspectives of the authors were augmented by scientific support from published citations and integrated with information derived from search engines (i.e., Chrome by Google, Inc) and chatbots (i.e., Chat Generative Pretrained Transformer or Chat GPT). Artificial Intelligence (AI) is the technologic acquisition of knowledge and skill by a nonhuman device, that after being initially programmed, has varying degrees of operations autonomous from direct human control, and that performs adaptive output tasks based upon data input learnings. AI has applications regarding medical research, medical practice, and applications relevant to the management of patients with obesity. Chatbots may be useful to obesity medicine clinicians as a source of clinical/scientific information, helpful in writings and publications, as well as beneficial in drafting office or institutional Policies and Procedures and Standard Operating Procedures. AI may facilitate interactive programming related to analyses of body composition imaging, behavior coaching, personal nutritional intervention & physical activity recommendations, predictive modeling to identify patients at risk for obesity-related complications, and aid clinicians in precision medicine. AI can enhance educational programming, such as personalized learning, virtual reality, and intelligent tutoring systems. AI may help augment in-person office operations and telemedicine (e.g., scheduling and remote monitoring of patients). Finally, AI may help identify patterns in datasets related to a medical practice or institution that may be used to assess population health and value-based care delivery (i.e., analytics related to electronic health records). AI is contributing to both an evolution and revolution in medical care, including the management of patients with obesity. Challenges of Artificial Intelligence include ethical and legal concerns (e.g., privacy and security), accuracy and reliability, and the potential perpetuation of pervasive systemic biases.
Clinical trials are an integral aspect of drug development. Tremendous progress has been made in ensuring drug products are effective and safe for use in the intended pediatric population, but there remains a paucity of information to guide drug dosages in pediatric patients with obesity. This is concerning because obesity may influence the disposition of drug products. When pediatric patients with obesity are not enrolled in clinical trials, dosing options for use in this subpopulation may be suboptimal. Reliance on physiological-based dosing strategies that are not informed by evaluation of the pharmacokinetics of the drug product could lead to under- or over-dosing with ensuing therapeutic failure or toxicity consequences. Thus, representation of pediatric patients with obesity in clinical trials is crucial to understand the benefit-risk profile of drug products in this subpopulation. It is important to acknowledge that this is a challenging endeavor, but not one that is insurmountable. Collective efforts from multiple stakeholders including drug developers and regulators to enhance diversity in clinical trials can help fill critical gaps in knowledge related to the influence of obesity on drug disposition.
An objective of the Precision Medicine Initiative, launched in 2015 by the US Food and Drug Administration and National Institutes of Health, is to optimize and individualize dosing of drugs, especially anticancer agents, with high pharmacokinetic and pharmacodynamic variability. The American Society of Clinical Oncology recently reported that 40% of obese patients receive insufficient chemotherapy doses and exposures, which may lead to reduced efficacy, and recommended pharmacokinetic studies to guide appropriate dosing in these patients. These issues will only increase in importance as the incidence of obesity in the population increases. This publication reviews the effects of obesity on (1) tumor biology, development of cancer, and antitumor response; (2) pharmacokinetics and pharmacodynamics of small-molecule anticancer drugs; and (3) pharmacokinetics and pharmacodynamics of complex anticancer drugs, such as carrier-mediated agents and biologics. These topics are not only important from a scientific research perspective but also from a drug development and regulator perspective. Thus, it is important to evaluate the effects of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents in all categories of body habitus and especially in patients who are obese and morbidly obese. As the effects of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents may be highly variable across drug types, the optimal dosing metric and algorithm for difference classes of drugs may be widely different. Thus, studies are needed to evaluate current and novel metrics and methods for measuring body habitus as related to optimizing the dose and reducing pharmacokinetic and pharmacodynamic variability of anticancer agents in patients who are obese and morbidly obese.
This study explores the impact of maternal pre-pregnancy BMI on infant neurodevelopment at 24 months in low-income Latino families. It also investigates whether infant diet mediates this relationship. Latino mother-infant pairs (n = 163) were enrolled at 1 month post partum and were followed for 2 years, with assessments at 6-month intervals. Maternal pre-pregnancy anthropometrics were self-reported at baseline, and child neurodevelopment was assessed at 24 months using the Bayley Scales of Infant Development. Diet quality of infants was measured using the Healthy Eating Index (HEI)-2015 and HEI-Toddlers-2020 scores at multiple time points. Mediation and regression models that adjust for maternal factors were used to examine the associations. Pre-pregnancy BMI showed significant negative associations with child cognitive scores (β = -0.1, 95% CI: -0.2 to -0.06, p < 0.001) and language scores (β = -0.1, 95% CI: -0.2 to -0.03, p = 0.01) at 24 months. Infant HEI-2015 scores at 24 months partly mediated these associations, explaining 23% and 30% of the total effect on cognitive and language subscales, respectively. No specific dietary components in infants mediated the relationship, except for the total HEI-2015 score. Managing maternal obesity pre-pregnancy is crucial for improving infant neurodevelopmental outcomes, especially in low-income Latino families. Promoting healthy weight and enhancing infant diet quality can enhance neurodevelopment in these populations.
This study aimed to examine the association of BMI with cognitive performance in individuals with diabetes or prediabetes. Among Diabetes Prevention Program Outcomes Study (DPPOS) participants, BMI was categorized as normal (< 25 kg/m2), overweight (25 to < 30 kg/m2), or obesity (≥ 30 kg/m2). Cognitive tests included the Brief Spanish English Verbal Learning Test (B-SEVLT) and the Digit Symbol Substitution test (DSST). The relationship between BMI at DPPOS Year 8 (Y8) visit and cognitive test scores at Y8, Y10, and Y15 visits was ascertained via linear mixed models accounting for repeated measures. Analogous models related BMI to Modified Mini-Mental State exam (3MS) score at Y15. A total of 2285 participants (mean ± SD age 51.1 ± 10.0 years; 67.7% female; 31% with overweight; and 60% with obesity at DPPOS Y8) completed cognitive assessments. Those with overweight or obesity at Y8 had a slower decline in B-SEVLT immediate and delayed recall, compared with those with normal BMI; 3MS performance was higher among individuals with overweight or obesity compared to those with normal BMI at Y15. Among individuals with prediabetes or diabetes in DPPOS, overweight or obesity was associated with slower decline in verbal learning and memory compared with those with normal BMI.
[This corrects the article DOI: 10.1016/j.obpill.2022.100044.].